BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會


Chris Wigley

Session 2 (Plenary) – Global Biotech Development

Date:27 July (Wednesday)
Time:  10:40 – 12:10 (GMT+8)

Chris Wigley

CEO Genomics England
Genomics England

Chris Wigley is the CEO of Genomics England, which exists to push insights from cutting edge genomics data analytics into routine medical care. As the national steward of 40 petabytes of human genome data from 100,000 volunteers, and a unique partnership with the NHS, Genomics England’s goal is to improve patient outcomes while lowering the cost of healthcare provision. Through the COVID crisis Chris was seconded as Senior Responsible Officer for Data to NHSX, and Genomics England launched a major research programme into the genomic drivers of severity of response to COVID. 

Chris was previously COO at QuantumBlack, a bespoke Machine Learning and AI technology company, and a Partner at McKinsey working on technology strategy topics. He is a trustee of the New Entrepreneurs Foundation, and on the Advisory Board of deep-tech VC Entrepreneur First. He previously worked for the UK Foreign Office, establishing and leading analytical work at the Counter Terrorism Policy Department to counter chemical, biological and nuclear terror threats. Chris lives in London with his wife Tara and their three children.

Speech title & Synopsis

Genomics England: enabling the next chapter of the UK’s contribution in genomics

Chris Wigley, CEO of Genomics England, talks about how Genomics England enables the UK to continue to be a leader in Genomics, and delivering the company vision: a world where everyone benefits from Geonomics Healthcare. 

The presentation will cover the UK’s history in the sector and where the country stands today. This will include Genomics England’s partnership with the National Health Service, to embed whole genome sequencing nationwide in clinical service for cancer and rare disease, as well as running an internationally accessible research environment containing over 53 petabytes of clinical and research data. This environment holding the data from research participants and patients from the National Health Service, gives researchers the tools to do research that will benefit patients whilst safeguarding the data. 

Finally, Chris will cover Genomics England’s next chapter. Launching a nationwide research pilot embedded in the healthcare system to use whole genome sequencing to screen newborns for rare disease, combining multiple types of data in one environment, testing new sequencing technologies to improve cancer outcomes, and how Genomics England are working to improve the diversity of their dataset to ensure the benefits of genomic healthcare and research are felt by everyone.